Simongrove

[Poolbeg Pharma @PoolbegPharma]

Poolbeg's POLB 001 programme and the TOPICAL clinical trial featured in the @RBLX_MENews, sharing the powerful story of Jason Walker and his determination to be there for his daughter’s future milestones.

POLB 001 is being evaluated as an oral preventative treatment for CRS, with the potential, if successful, to reduce treatment burden, support safer delivery of immunotherapies and enable more patients to receive treatment closer to home.

As cancer immunotherapies become increasingly important, the need for effective CRS prevention represents a significant clinical and commercial opportunity for Poolbeg’s differentiated approach.

👉 Read Jason’s story and the full article:

https://t.co/aktPeuydZC

#PoolbegPharma #POLB001 #CancerImmunotherapy #MultipleMyeloma

[Poolbeg Pharma @PoolbegPharma]

Jason Walker, the first participant in the POLB 001 TOPICAL clinical trial spoke with the @BBC sharing his experience of living with multiple myeloma and taking part in research that could help improve the delivery of cancer immunotherapies.

"If it works it could be something which could improve treatment not just for me but for other people living with myeloma."

With CRS remaining a major barrier to wider use of these transformative treatments, preventing it could help reduce hospitalisation and ultimately bring treatment closer to patients’ homes.

Clinical trials are only possible because of the patients, families, investigators and healthcare professionals who choose to participate. We are grateful to everyone involved in the TOPICAL clinical trials.

Read the BBC article below ⬇️

https://t.co/di5TZJNIZF

#POLB #PoolbegPharma #POLB001 #ClinicalTrials #MultipleMyeloma #CancerImmunotherapy #CRS #Oncology #Patients

[Poolbeg Pharma @PoolbegPharma]

📰 “Three weeks ago Jason, now 57, started 14 cycles of treatment and has been feeling great, attending circuit training as the new drug appears to be stopping the side-effects of immunotherapy.” Powerful coverage in the @Daily_Express highlighting the TOPICAL trial and its first patient, Jason Walker, who has lived with multiple myeloma for 12 years.

The trial is evaluating #POLB 001 as an oral preventative treatment for Cytokine Release Syndrome (CRS), a common side effect of powerful cancer immunotherapies.

If successful, preventing CRS could help more patients access these transformative treatments, reduce hospitalisation and support care closer to home.

“I hope it works, not just for myself, but for the wider myeloma warriors out there.” – Jason Walker

https://t.co/CQ3yLQZrgM

#Biotech #MultipleMyeloma #CancerResearch

[Poolbeg Pharma @PoolbegPharma]

If you missed yesterday's announcement, then you can catch up with @VOXmarkets.

Our CEO Jeremy Skillington & Principal Scientist Liam Tremble discuss how POLB 001 will feature in the groundbreaking RISE programme, which is a major research initiative tackling CRS, a serious side effect of advanced cancer immunotherapies.

RISE, led by The University of Manchester and The Christie NHS Foundation Trust, aims to improve understanding of CRS and make cancer treatments safer. The POLB 001 Phase 2a TOPICAL trial will be a key feature of the programme with Johnson & Johnson providing teclistamab, free of charge, for trial.

For patients, POLB 001 could revolutionise cancer care, enabling safer delivery, reducing hospital burden & expanding access to life-saving treatments.

Watch the full interview here:
https://t.co/hTK4IAOydW

#POLB #VOXMarkets #AIM #ScientificResearch #CRS #Oncology #Pharma

[hVIVO @hVIVO_UK]

We presented positive data from a number of newly development human challenge models at leading scientific conferences @ESWInfluenza & the @vaccinenation World Vaccine Congress Europe.

🔬 hMPV Challenge Model – The world’s only contemporary-strain hMPV challenge model, now ready for vaccine and antiviral trials.

🔬 SARS-CoV-2 Omicron Challenge Model - The first commercially available SARS-CoV-2 Omicron BA5 challenge model, enabling studies in real-world conditions.
🔬 RSV B Challenge Model – A key component of our next-generation combination vaccine testing platform.

The positive data across all human challenge models reinforces hVIVO’s continued world-leading capabilities in accelerating the development of novel challenge agents and ability to meet customer demand for innovative and effective clinical trial solutions.

Read full announcement here:
https://t.co/eoYHjXzx66

#HVO #HumanChallenge #HCT #CHIM #ChallengeTrials #ChallengeModels #hMPV #COVID #SARSCOV2 #ScientificResearch #InfectiousDisease #ESWI #WVC

[David Burton ⭐️⭐️ @DavidBurton1971]

New note out on @PoolbegPharma

19p t/p for #POLB

You can buy around 3p 🤩

[Novus Comms @NovusComms]

#POLB @PoolbegPharma presents at the 66th @ASH_hematology annual meeting

✅ All doses of POLB 001 significantly reduced CRS scores
✅ Positive results reinforce use case for POLB 001 in the prevention & treatment of #cancer immunotherapy-induced CRS

https://t.co/w1wTSAzPhV

[hVIVO @hVIVO_UK]

If you were unable to attend last nights @InvestorMeetCo presentation featuring our CEO & CFO, you can now watch & catch up on the link below 🚀

https://t.co/zxK3M0g9B1

#HVO #InvestorMeetCo #AIM #Interims

[Poolbeg Pharma @PoolbegPharma]

We are using #AI to extract valuable insights from high precision matched data from human challenge trials. We have already identified a number of exciting drug targets and treatments and are looking to partner to progress these towards the clinic.

https://t.co/gNteLwpIm1

#POLB

[hVIVO @hVIVO_UK]

In April we opened the world’s largest commercial human challenge trial unit in #CanaryWharf! 🚀

🏙️ The @flucamp volunteers have enjoyed the new state-of-the-art quarantine facility!

📣Stay tuned for updates on the corporate office and laboratory move, coming soon!

#HVO

[Darren-Uk Trading. @Darrenukdaytra1]

#POLB it’s retraced 1fib and testing the ATH on the weekly. Rsi, Macd and Aroon direction are all positive. Looking good. DYOR

[hVIVO @hVIVO_UK]

Mark your calendars 📅 we will be releasing our full year results for the year ended 31 December 2023 on Tuesday 9 April 2024.

Our CEO & CFO will be presenting on @InvestorMeetCo at 6pm that evening.

Learn more:
https://t.co/Tmx3Gfisvn

#HVO

[hVIVO @hVIVO_UK]

We featured in todays @FT "The hunt for good-value UK stocks"🚀

“London is stuffed full of quality companies..such as hVivo.."

With a strong financial profile, #HVO is scaling & driving efficiencies to deliver on our long term sustainable growth model

https://t.co/7WUOARzrS3

[Simongrove @simongrove]

@hVIVO_UK Well done guys, keep up the good work! 👏🏻👏🏻

[hVIVO @hVIVO_UK]

FY23 Trading Update #HVO

✅ £56m revenue
📈 c.22% EBITDA margins
💰 £37m cash
📚 £80m weighted contracted orderbook
🔍£62m revenue guidance for 2024 with 90% contracted
📅 Nominal annual dividend
🎯New medium-term target of £100m revenue by 2028

https://t.co/Q7Ysy6v1SU

[hVIVO @hVIVO_UK]

Case Study Alert! 📢 A US-based clinical-stage biopharma company contracted #HVO to conduct an #Influenza challenge study. Learn more about the challenges & results, which resulted Fast-track designation awarded by the @US_FDA.

Download here⬇️
https://t.co/LwFBYKv58O

[Flexiheat UK @flexiheatuk]

Commercial air source heat pumps – maximizing energy efficiency for businesses. With a range from 12.5kW up to 74.6 kW of heating and 11.3kW to 64.8 kW of cooling in single units, that we can cascade up to 8 units, A++ efficiency.
https://t.co/2ALZiywHhK

[hVIVO @hVIVO_UK]

We have signed a £6.3m contract with a biotech client to test its antiviral candidate using #HVO's HRV (common cold) human challenge study model.

The multi-cohort trial is due to commence in H2 24 at our new state-of-the-art facilities in #CanaryWharf.

https://t.co/QNl9gbz0uY

[hVIVO @hVIVO_UK]

£16.8m full-service #RSV contract with a top 5 global #pharma client:

🔬Expedited manufacture of RSV challenge agent
👩‍🔬Confirmatory challenge cohort
🦠Multiple cohort challenge trial

Plus, #HVO is trading ahead of previous market expectation!

Learn more
https://t.co/ArLDa4F8rj

[hVIVO @hVIVO_UK]

Our Chief Scientific Officer featured in a #WVC interview at @vaccinenation Santa Clara:

💪 The power of Human Challenge Trials
🦠 #HVO's Human Challenge Models
🏙️ How Canary Wharf facility will further improve efficiency for our clients

https://t.co/GUBf2xkyhY

#WVC2023 #WVC